CA
NZ
UK
AU
IND
US
…
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 | 2019-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 | 2019-08-31 |
| Income before tax | -10.08M | -10.08M | -7.44M | -4.65M | -2.17M |
| Net income | -9.87M | -10.08M | -7.44M | -4.65M | -2.17M |
| Selling general administrative | 5.96M | 5.96M | 4.60M | 2.77M | 2.12M |
| Reconciled depreciation | - | - | - | 0.00M | 0.00M |
| Ebit | -10.29M | - | -7.44M | -4.72M | -4.22M |
| Ebitda | -10.29M | -10.08M | -7.44M | -4.71M | -4.22M |
| Depreciation and amortization | 0.00M | - | -0.00M | 0.00M | 0.00M |
| Operating income | -10.29M | -10.29M | -7.44M | -4.69M | -3.21M |
| Other operating expenses | 10.29M | - | 7.44M | 4.69M | 3.21M |
| Interest expense | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | 0.00M | 0.00M | - | 1.01M |
| Net interest income | - | -0.00M | 0.00M | - | - |
| Income tax expense | -0.21M | - | -0.00M | -0.06M | -2.04M |
| Total revenue | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 10.29M | 10.29M | 7.44M | 4.69M | 3.21M |
| Total other income expense net | 0.20M | 0.21M | 0.00M | 0.03M | 1.04M |
| Net income from continuing ops | - | -10.08M | -7.44M | -4.65M | -2.17M |
| Net income applicable to common shares | - | - | - | - | -2.17M |
| Breakdown | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 | 2019-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 | 2019-08-31 |
| Total assets | 20.42M | 20.42M | 12.63M | 4.38M | 6.48M |
| Intangible assets | 2.04M | 2.04M | 2.04M | 2.04M | 2.04M |
| Other current assets | 0.79M | 0.79M | 0.25M | 0.20M | 0.02M |
| Total liab | 1.02M | 1.02M | 0.59M | 0.50M | 1.02M |
| Total stockholder equity | 19.40M | 19.40M | 12.04M | 3.87M | 5.46M |
| Other current liab | 0.05M | - | 0.01M | 0.01M | 0.67M |
| Common stock | 0.00M | - | 0.03M | 0.00M | 0.00M |
| Capital stock | - | 0.00M | 0.03M | 0.00M | 0.00M |
| Retained earnings | -31.02M | -31.02M | -16.90M | -9.47M | -4.81M |
| Other assets | - | - | - | 0.00M | - |
| Cash | 6.89M | 6.89M | 6.63M | 2.14M | 4.42M |
| Total current liabilities | 1.00M | 1.00M | 0.53M | 0.50M | 1.02M |
| Net debt | -6.83M | - | -6.53M | -2.14M | -4.42M |
| Short term debt | 0.04M | - | 0.03M | - | 0.00M |
| Short long term debt total | 0.06M | - | 0.10M | - | 0.00M |
| Other stockholder equity | 50.67M | - | 28.90M | 13.27M | 10.28M |
| Property plant equipment | - | - | - | - | 0.00M |
| Total current assets | 18.32M | 18.32M | 10.32M | 2.34M | 4.44M |
| Long term investments | - | 0.00M | - | - | - |
| Short term investments | 10.64M | 10.64M | 3.44M | - | 0.00M |
| Net receivables | - | - | - | - | 0.01M |
| Inventory | - | - | - | - | -0.01M |
| Accounts payable | 0.91M | 0.91M | 0.49M | 0.49M | 0.35M |
| Accumulated other comprehensive income | -0.25M | - | 0.02M | 0.06M | -0.01M |
| Common stock total equity | - | - | - | - | 0.00M |
| Non currrent assets other | 0.00M | 0.00M | 0.19M | - | - |
| Non current assets total | 2.10M | 2.10M | 2.32M | 2.04M | 2.04M |
| Capital lease obligations | - | 0.06M | 0.10M | - | - |
| Breakdown | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 | 2019-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 | 2019-08-31 |
| Investments | - | 2.96M | -3.44M | 0.00M | -1.50M |
| Total cashflows from investing activities | - | - | - | - | -1.50M |
| Total cash from financing activities | -0.04M | 0.00M | 14.11M | 1.98M | 8.38M |
| Net income | -10.08M | -10.08M | -7.44M | -4.65M | -2.17M |
| Change in cash | -5.27M | -5.27M | 4.49M | -2.28M | 4.09M |
| Begin period cash flow | 12.16M | 12.16M | 2.14M | 4.42M | 0.34M |
| End period cash flow | 6.89M | 6.89M | 6.63M | 2.14M | 4.42M |
| Total cash from operating activities | -8.01M | -8.01M | -6.14M | -4.35M | -2.79M |
| Issuance of capital stock | - | 0.00M | 8.10M | 1.98M | 8.38M |
| Depreciation | - | - | - | 0.00M | 0.00M |
| Sale purchase of stock | - | - | - | -0.00M | -4.42M |
| Other cashflows from financing activities | 0.04M | - | 6.01M | 0.00M | 0.00M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 1.50M |
| Change in working capital | -0.17M | -0.17M | -0.24M | -0.04M | -0.14M |
| Stock based compensation | 2.46M | 2.46M | 1.53M | 0.38M | 0.43M |
| Other non cash items | -0.21M | -0.00M | 0.01M | -0.03M | 0.10M |
| Free cash flow | -8.01M | -8.01M | -6.14M | -4.35M | -4.29M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
0.85 2.22% |
39.14 | 41.58 | 31.15 | 2.13 | 32.99 |
| VRTX Vertex Pharmaceuticals Inc |
10.31 1.95% |
540.00 | 30.22 | 24.27 | 10.36 | 6.50 |
| REGN Regeneron Pharmaceuticals Inc |
5.50 0.68% |
818.77 | 29.07 | 20.12 | 7.57 | 3.82 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 |
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. Gregory D. Gorgas M.B.A. | President, CEO, CFO, Treasurer, Secretary & Director | 1963 |
| Dr. Andrew Yates Ph.D. | Senior VP & Chief Scientific Officer | NA |
| Dr. Steven D. Reich | Chief Medical Officer | 1946 |
| Mr. Jason H. Baybutt | Senior Vice President of Finance | 1972 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.52%
Communication Services
+0.32%
Consumer Cyclical
+1.01%
Consumer Defensive
+0.00%
Energy
+0.01%
Financial Services
+0.62%
Financials
-2.62%
Healthcare
+0.51%
Industrials
+0.71%
Real Estate
+0.72%
Technology
-0.46%
Utilities
+0.54%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...